Reva Medical,a development stage medical device company, has begun patient enrollment in a Pilot Study of the ReZolve Sirolimus-Eluting Bioresorbable Coronary Scaffold (RESTORE) trial, to evaluate its ReZolve bioresorbable sirolimus-eluting coronary scaffold.

Continue reading here:
Reva commences patient enrollment in RESTORE pilot trial